Johnson & Johnson (NYSE:JNJ) Shares Bought by Mcdaniel Terry & Co.

Posted by Defense World Staff on Apr 5th, 2023

Mcdaniel Terry & Co. increased its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.3% during the fourth quarter, HoldingsChannel reports. The fund owned 181,702 shares of the company’s stock after buying an additional 556 shares during the period. Johnson & Johnson comprises about 3.7% of Mcdaniel Terry & Co.’s investment portfolio, making the stock its 6th largest position. Mcdaniel Terry & Co.’s holdings in Johnson & Johnson were worth $32,098,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Glassy Mountain Advisors Inc. acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $35,000. Retirement Financial Solutions LLC bought a new position in Johnson & Johnson in the fourth quarter valued at $40,000. TD Capital Management LLC bought a new stake in Johnson & Johnson during the 3rd quarter worth about $48,000. Iron Horse Wealth Management LLC boosted its stake in shares of Johnson & Johnson by 112.8% during the 4th quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock worth $53,000 after buying an additional 159 shares during the last quarter. Finally, Piershale Financial Group Inc. bought a new position in shares of Johnson & Johnson in the 4th quarter valued at about $61,000. 67.94% of the stock is owned by institutional investors.

Insider Activity

In related news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the transaction, the insider now directly owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.20% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several analysts recently issued reports on JNJ shares. Atlantic Securities upped their target price on Johnson & Johnson from $160.00 to $168.00 and gave the stock a “neutral” rating in a report on Wednesday, January 25th. Citigroup increased their price objective on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a report on Monday, December 12th. UBS Group initiated coverage on shares of Johnson & Johnson in a report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 target price on the stock. Guggenheim initiated coverage on shares of Johnson & Johnson in a research note on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price target for the company. Finally, Piper Sandler lowered their price objective on shares of Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. Eight investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $173.67.

Johnson & Johnson Trading Up 1.0 %

Shares of JNJ stock opened at $158.49 on Wednesday. Johnson & Johnson has a 12-month low of $150.11 and a 12-month high of $186.69. The company has a market capitalization of $412.75 billion, a PE ratio of 23.51, a price-to-earnings-growth ratio of 2.67 and a beta of 0.53. The firm has a 50 day moving average price of $157.59 and a two-hundred day moving average price of $167.05. The company has a quick ratio of 0.77, a current ratio of 0.99 and a debt-to-equity ratio of 0.35.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, topping the consensus estimate of $2.22 by $0.13. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The business had revenue of $23.71 billion during the quarter, compared to analysts’ expectations of $23.90 billion. During the same period last year, the firm posted $2.13 EPS. The firm’s revenue for the quarter was down 4.4% compared to the same quarter last year. As a group, analysts predict that Johnson & Johnson will post 10.5 earnings per share for the current year.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.